A Phase 2 interventional study of Erlotinib and Gemcitabine in Pancreatic Cancer, sponsored by Hoffmann-La Roche. Completed at 29 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing erlotinib in Pancreatic Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. erlotinib · Pancreatic Neoplasms.
Among the 53 studies testing erlotinib in Pancreatic Neoplasms, this one is the 7th largest by enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2007, is one of 27 in phase 2, and was the 18th registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →1 of the 53 studies testing erlotinib in Pancreatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
erlotinib: first FDA approval 2004 (TARCEVA), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 32 · Phase 3 4
First in 2001; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 32 across the 52 interventional studies. Of the 46 that completed or were terminated, 22 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 53 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
16 studies in Pancreatic Neoplasms by Hoffmann-La Roche: none open now, 1 under way, none of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 16 studies in Pancreatic Neoplasms by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2007, is one of 7 in phase 2, and was the 1st registered.
Hoffmann-La Roche’s Pancreatic Neoplasms studies by the year they started, since 2003.
1 of the studies testing erlotinib in Pancreatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06483555UNC Lineberger Comprehensive Cancer CenterBasal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing erlotinib in Pancreatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 16 in Pancreatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the relationship between the skin toxicity of Tarceva in combination with gemcitabine, and survival, in patients with advanced and/or metastatic pancreatic cancer. All patients will receive gemcitabine 100mg/m2 i.v. weekly; Tarceva will be administered 100mg po per day. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a rash graded less than (\<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m\^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
Drug: Erlotinib · Drug: Gemcitabine
Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m\^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
Drug: Erlotinib · Drug: Gemcitabine
100 mg, PO, once per day
Also known as: Tarceva
1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
Number of Participants Who Died During the Study
Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Overall Survival (OS) During the Study
OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.
Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Number of Participants Who Died at 6 Months
Time frame: Enrollment through Cycle 6 (4-week cycles), up to 6 months.
OS At 6 Months
OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.
Time frame: Enrollment through Cycle 6 (4-week cycles), up to 6 months.
Number of Participants Who Died During the Study By Rash Grade
Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.
OS By Rash Grade
OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.
Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Number of Participants With Disease Progression or Death
Progression-free survival (PFS) was defined as the time from the date of enrollment to the date of document disease progression or death due to any cause. As per Response Evaluation Criteria in Solid Tumors (RECIST) V 1.0, progressive disease (PD) was defined for target lesions (TLs) as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded since the start of treatment, and for non-target lesions (NTLs) as unequivocal progression of NTLs. Participants whose last recorded status was not PD or death were censored.
Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.
PFS
The time, in months, from enrollment to PFS event. Participants whose last recorded status was not progression or death were censored. PFS was estimated using Kaplan-Meier methodology.
Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST
As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline (BL) SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.
Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.
Percentage of Participants With Disease Control According to RECIST
Disease control was defined as BOR of CR, PR, or stable disease (SD). As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.
Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.
| Milestone | Erlotinib, Gemcitabine: Rash Grade Less Than (<) 2 | Erlotinib, Gemcitabine: Rash Grade Greater Than/Equal to (≥) 2 |
|---|---|---|
| Started | 115 | 38 |
| Completed | 0 | 0 |
| Not completed | 115 | 38 |
| Withdrew: Adverse event | 17 | 7 |
| Withdrew: Lack of efficacy | 68 | 20 |
| Withdrew: Physician decision | 10 | 4 |
| Withdrew: Withdrawal by subject | 8 | 2 |
| Withdrew: Other | 4 | 4 |
| Withdrew: Death | 8 | 1 |
| participants | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Number of Participants Who Died During the Study | 102 | 27 |
OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.
| months | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Overall Survival (OS) During the Study | 4.468 (3.618 to 5.318) | 10.546 (9.679 to 11.414) |
| participants | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Number of Participants Who Died at 6 Months | 69 | 8 |
OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.
| months | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| OS At 6 Months | 4.468 (3.618 to 5.318) | NA (NA to NA) |
| participants | Erlotinib, Gemcitabine: Rash Grade 0 | Erlotinib, Gemcitabine: Rash Grade 1 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|---|
| Number of Participants Who Died During the Study By Rash Grade | 65 | 37 | 27 |
OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.
| months | Erlotinib, Gemcitabine: Rash Grade 0 | Erlotinib, Gemcitabine: Rash Grade 1 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|---|
| OS By Rash Grade | 3.318 (2.446 to 4.191) | 6.571 (5.139 to 8.003) | 10.546 (9.679 to 11.414) |
Progression-free survival (PFS) was defined as the time from the date of enrollment to the date of document disease progression or death due to any cause. As per Response Evaluation Criteria in Solid Tumors (RECIST) V 1.0, progressive disease (PD) was defined for target lesions (TLs) as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded since the start of treatment, and for non-target lesions (NTLs) as unequivocal progression of NTLs. Participants whose last recorded status was not PD or death were censored.
| participants | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Number of Participants With Disease Progression or Death | 110 | 33 |
The time, in months, from enrollment to PFS event. Participants whose last recorded status was not progression or death were censored. PFS was estimated using Kaplan-Meier methodology.
| months | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| PFS | 2.497 (2.130 to 2.864) | 6.439 (4.919 to 7.960) |
As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline (BL) SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.
| percentage of participants | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST | 7.0 | 21.1 |
Disease control was defined as BOR of CR, PR, or stable disease (SD). As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.
| percentage of participants | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Percentage of Participants With Disease Control According to RECIST | 42.6 | 84.2 |
Collected over Adverse events (AEs) were recorded at every study visit for up to a maximum of 24 treatment cycles.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Erlotinib, Gemcitabine: Rash Grade < 2 | — | 58/115 (50.4%) | 115/115 (100%) |
| Erlotinib, Gemcitabine: Rash Grade ≥ 2 | — | 14/38 (36.8%) | 38/38 (100%) |
| Event | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| Obstruction, GIGastrointestinal disorders | 11/115 | 2/38 |
| Lung (pneumonia)Infections and infestations | 3/115 | 3/38 |
| FeverGeneral disorders | 4/115 | 2/38 |
| BloodInfections and infestations | 4/115 | 2/38 |
| CNS Cerebrovascular ischemiaNervous system disorders | 1/115 | 2/38 |
| Abdomen nosGastrointestinal disorders | 5/115 | 0/38 |
| FatigueGeneral disorders | 4/115 | 1/38 |
| Haemorrhage, GIGastrointestinal disorders | 3/115 | 1/38 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/115 | 1/38 |
| Left ventricular dysfunctionCardiac disorders | 0/115 | 1/38 |
| Event | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 |
|---|---|---|
| FatigueGeneral disorders | 89/115 | 31/38 |
| Abdomen nosMusculoskeletal and connective tissue disorders | 78/115 | 19/38 |
| AnorexiaMetabolism and nutrition disorders | 62/115 | 11/38 |
| DiarrheaGastrointestinal disorders | 55/115 | 15/38 |
| NeutropeniaBlood and lymphatic system disorders | 20/115 | 16/38 |
| NauseaGastrointestinal disorders | 43/115 | 12/38 |
| ConstipationGastrointestinal disorders | 38/115 | 12/38 |
| VomitingGastrointestinal disorders | 34/115 | 8/38 |
| FeverGeneral disorders | 18/115 | 11/38 |
| AnaemiaBlood and lymphatic system disorders | 32/115 | 11/38 |
Intent-to-treat (ITT) population: all participants included in the study.
| Age, Continuous(years) | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 | Total |
|---|---|---|---|
| Mean | 63.6 ± 9.9 | 62.0 ± 10.6 | 63.2 ± 10.1 |
| Sex: Female, Male(Participants) | Erlotinib, Gemcitabine: Rash Grade < 2 | Erlotinib, Gemcitabine: Rash Grade ≥ 2 | Total |
|---|---|---|---|
| Female | 61 | 10 | 71 |
| Male | 54 | 28 | 82 |
The record gives a start of May 2007, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Erlotinib · Gemcitabine